S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
ETR:MOR

MorphoSys (MOR) Stock Price, News & Analysis

€67.20
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
€67.20
€67.24
50-Day Range
€33.42
€67.22
52-Week Range
€13.81
€66.82
Volume
100,985 shs
Average Volume
153,687 shs
Market Capitalization
$2.53 billion
P/E Ratio
N/A
Dividend Yield
1.26%
Price Target
N/A
MOR stock logo

About MorphoSys Stock (ETR:MOR)

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MOR Stock Price History

MOR Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
MorphoSys: Q4 Earnings Insights
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
MorphoSys just downgraded at JMP Securities, here's why
Novartis And MorphoSys Are A Perfect Match
MorphoSys AG ADR MOR
DAX Edges Higher As Investors Await GDP Data
European Shares Slightly Higher; Flash Eurozone GDP Data Awaited
MorphoSys To Issue 3.423 Mln New Shares At EUR 30/shr
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
524
Year Founded
N/A

Profitability

Net Income
$-189,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$238.28 million
Cash Flow
€129.63 per share
Book Value
€1.30 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.53 billion
Optionable
Not Optionable
Beta
0.61
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jean-Paul Kress M.D. (Age 59)
    Chairman of Management Board, MD & CEO
    Comp: $1.76M
  • Dr. Lucinda Crabtree Ph.D. (Age 45)
    CFO & Member of Management Board
    Comp: $705.82k
  • Ms. Charlotte Lohmann (Age 54)
    Chief Legal and Human Resources Officer & Member of Management Board
    Comp: $474.1k
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Julia Neugebauer Ph.D.
    Head of Investor Relations
  • Dr. Barbara Krebs-Pohl Ph.D.
    Chief Business Officer
  • Dr. Günter Wellnhofer
    Head of Technical Operations
  • Dr. Harald Watzka
    Head of Alliance Management
  • Ms. Yen Ching Chua
    Head of Clinical Operations

MOR Stock Analysis - Frequently Asked Questions

How have MOR shares performed in 2024?

MorphoSys' stock was trading at €34.00 at the beginning of the year. Since then, MOR shares have increased by 97.6% and is now trading at €67.20.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of MorphoSys own?
This page (ETR:MOR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners